NASDAQ:ILMN - Illumina Stock Price, Forecast & News

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Illumina, Inc. (NASDAQ:ILMN) posted its quarterly earnings data on Thursday, October, 24th. The life sciences company reported $1.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.53. The life sciences company had revenue of $907 million for the quarter, compared to the consensus estimate of $872.65 million. Illumina had a return on equity of 22.05% and a net margin of 28.14%. The business's revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.52 EPS. View Illumina's Earnings History.

Illumina is scheduled to release their next quarterly earnings announcement on Wednesday, January 29th 2020. View Earnings Estimates for Illumina.

Illumina updated its fourth quarter 2019 After-Hours earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $950-950 million, compared to the consensus revenue estimate of $939.29 million.

16 equities research analysts have issued 12-month price targets for Illumina's stock. Their forecasts range from $280.00 to $385.00. On average, they anticipate Illumina's share price to reach $339.73 in the next twelve months. This suggests a possible upside of 8.1% from the stock's current price. View Analyst Price Targets for Illumina.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Illumina.

Headlines about ILMN stock have trended negative on Wednesday, according to InfoTrie. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Illumina earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned media headlines about the life sciences company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the next few days. View News Stories for Illumina.

Illumina saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 3,610,000 shares, an increase of 8.4% from the December 15th total of 3,330,000 shares. Based on an average daily trading volume, of 868,000 shares, the short-interest ratio is currently 4.2 days. Currently, 2.5% of the company's stock are sold short. View Illumina's Current Options Chain.

Some companies that are related to Illumina include Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), PerkinElmer (PKI), Bio-Rad Laboratories (BIO), BIO-TECHNE (TECH), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Walt Disney (DIS), Visa (V), Baidu (BIDU), Adobe (ADBE), Tesla (TSLA), Paypal (PYPL) and Micron Technology (MU).

Illumina's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Douglas Lane & Associates LLC (0.25%), California Public Employees Retirement System (0.23%), New York State Teachers Retirement System (0.13%), KAMES CAPITAL plc (0.12%), Strs Ohio (0.10%) and Waverton Investment Management Ltd (0.10%). Company insiders that own Illumina stock include A Blaine Bowman, Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi. View Institutional Ownership Trends for Illumina.

ILMN stock was sold by a variety of institutional investors in the last quarter, including First Hawaiian Bank, Strs Ohio, Global Thematic Partners LLC, Spence Asset Management, Waverton Investment Management Ltd, Premier Asset Management LLC, Meag Munich Ergo Kapitalanlagegesellschaft MBH and Gateway Investment Advisers LLC. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi. View Insider Buying and Selling for Illumina.

ILMN stock was purchased by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Assenagon Asset Management S.A., Capital Investment Services of America Inc., Vigilant Capital Management LLC, Virginia Retirement Systems ET AL, California Public Employees Retirement System, Meritage Portfolio Management and M&G Investment Management Ltd.. View Insider Buying and Selling for Illumina.

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ILMN stock can currently be purchased for approximately $314.28.

Illumina has a market capitalization of $46.20 billion and generates $3.33 billion in revenue each year. The life sciences company earns $826 million in net income (profit) each year or $5.72 on an earnings per share basis. Illumina employs 7,300 workers across the globe.View Additional Information About Illumina.

The official website for Illumina is http://www.illumina.com/.

Illumina's mailing address is 5200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]